TABLE 2p. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories, and Non-U.S. Residents, 2022† column labels in same order that data fields appears in each record below: Reporting Area Spotted fever rickettsiosis, Total Spotted fever rickettsiosis, Confirmed Spotted fever rickettsiosis, Probable Streptococcal toxic shock syndrome Syphilis, Total, all stages § Syphilis, Congenital Syphilis, Primary and secondary tab delimited data: U.S. Residents, excluding U.S. Territories 1,292 47 1,245 333 207,223 3,755 59,010 New England 19 — 19 41 4,025 29 1,359 Connecticut 1 — 1 17 731 7 243 Maine 1 — 1 16 154 3 82 Massachusetts 15 — 15 5 2,444 11 824 New Hampshire — — — — 175 3 74 Rhode Island — — — — 516 5 133 Vermont 2 — 2 3 5 — 3 Middle Atlantic 48 2 46 43 21,786 137 6,018 New Jersey 35 2 33 25 3,615 48 1,018 New York (excluding New York City) 3 — 3 15 3,586 32 1,303 New York City 7 — 7 — 10,099 18 2,300 Pennsylvania 3 — 3 3 4,486 39 1,397 East North Central 87 4 83 78 17,906 275 6,259 Illinois 18 1 17 48 5,734 85 1,457 Indiana 10 1 9 24 2,129 38 686 Michigan 8 — 8 4 2,824 36 972 Ohio 40 2 38 2 5,300 90 2,402 Wisconsin 11 — 11 — 1,919 26 742 West North Central 180 8 172 23 10,587 176 3,856 Iowa 10 1 9 N 886 8 334 Kansas 34 3 31 — 958 13 347 Minnesota — — — 10 1,839 20 675 Missouri 128 2 126 12 4,176 82 1,454 Nebraska 7 2 5 — 653 11 215 North Dakota — — — — 128 2 64 South Dakota 1 — 1 1 1,947 40 767 South Atlantic 374 17 357 82 43,339 553 12,750 Delaware 4 — 4 — 435 4 238 District of Columbia — — — — 1,275 12 271 Florida 10 — 10 N 18,838 276 4,618 Georgia 40 1 39 47 7,361 101 2,182 Maryland 16 1 15 — 2,798 45 781 North Carolina 202 14 188 22 6,587 57 2,473 South Carolina 21 1 20 3 2,473 25 1,033 Virginia 69 — 69 10 2,962 20 936 West Virginia 12 — 12 — 610 13 218 East South Central 329 2 327 5 12,252 212 3,898 Alabama 118 1 117 N 3,087 43 1,190 Kentucky 96 — 96 4 2,031 35 669 Mississippi 21 — 21 N 3,260 73 913 Tennessee 94 1 93 1 3,874 61 1,126 West South Central 187 3 184 3 37,757 1,216 8,159 Arkansas 133 2 131 1 2,818 69 1,001 Louisiana 10 — 10 2 4,453 115 1,225 Oklahoma 25 — 25 N 3,501 110 1,278 Texas 19 1 18 N 26,985 922 4,655 Mountain 50 4 46 58 18,393 413 5,434 Arizona 38 2 36 1 7,496 219 2,151 Colorado 2 — 2 1 3,100 31 918 Idaho 6 1 5 — 350 — 118 Montana 2 1 1 2 629 15 325 Nevada 1 — 1 10 3,610 65 902 New Mexico — — — — 2,469 76 761 Utah 1 — 1 43 673 7 238 Wyoming — — — 1 66 — 21 Pacific 18 7 11 — 41,178 744 11,277 Alaska N N N N 423 12 160 California 12 5 7 N 33,346 616 7,849 Hawaii N N N — 606 27 231 Oregon 4 1 3 N 2,393 37 1,117 Washington 2 1 1 N 4,410 52 1,920 U.S. Territories — — — — 1,480 5 388 American Samoa N N N N — — — Commonwealth of Northern Mariana Islands — — — — 4 — — Guam N N N — 19 — 2 Puerto Rico N N N N 1,424 5 380 U.S. Virgin Islands — — — — 33 — 6 Non-U.S. Residents — — — — 33 — 6 Total 1,292 47 1,245 333 208,736 3,760 59,404 —: No reported cases - The reporting jurisdiction did not submit any cases to CDC. N: Not reportable - The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. U: Unavailable - The data are unavailable. * Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/. † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions uses population subgroups as described in note #7 and population counts presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection; Perinatal Hepatitis C infection; Haemophilus influenzae, invasive disease; Invasive pneumococcal disease; and Influenza-associated pediatric mortality. Also see Notes #3 and #7. § Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis. ¶ Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth. Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the https://ndc.services.cdc.gov/, Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf, https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also https://www.cdc.gov/nndss/data-statistics/readers-guides/index.html, Guide to Interpreting Provisional and Finalized NNDSS Data. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/">https://seer.cancer.gov/popdata/. For more information, see Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022, https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. Annual tables for 2016 and later years are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993–2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, Morbidity and Mortality Weekly Report. NNDSS annual tables since 1952 are available at https://stacks.cdc.gov/, CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports". For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations. Age restrictions in the numerator and denominator are applied for the following childhood conditions: Zika virus disease, congenital (age restriction in numerator and denominator is <1 year) Zika virus infection, congenital (age restriction in numerator and denominator is <1 year) Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years) Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years) Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years) Infant botulism (age restriction in numerator and denominator is <1 year) Congenital rubella syndrome (age restriction in numerator and denominator is <1 year) Perinatal hepatitis B infection (age restriction is ≤24 months) Perinatal hepatitis C infection (age restriction is ≤36 months). Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics https://wonder.cdc.gov/natality.html, Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC). Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations. Suggested Citation: Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2022 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Office of Public Health Data, Surveillance, and Technology, 2024. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html, https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html. Acknowledgment: CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System. https://www.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER